Largest Indian CRDMO platform offering comprehensive solutions across the drug development lifecycle for both small molecules and biologics with a "follow the customer" model.
Leading CRO platform in India powered by advanced capabilities and superior scientific talent.
Scalable CDMO solutions comprising small molecules and differentiated gene-to-GMP biologics capabilities with a distinctive US-India delivery model.
Diversified revenue profile with deep and long-standing relationships with global pharmaceutical customers and proven `Follow the customer' model
Strategically located advanced infrastructure across India and United states with strong track record of regulatory compliance.
Professional management for long term sustainable performance.
We are dependent on the continued outsourcing of research and development by innovator pharmaceutical and biotechnology companies. We derived a substantial portion of our revenue from operations from our CRO solutions in Fiscals 2026, 2025 and 2024 representing 64.51%, 65.78% and 67.15%, respectively, of our revenue from operations. Any adverse trends in the outsourcing practices or reduction in demand for outsourcing by innovator pharmaceutical and biotechnology companies could adversely affect our business, results of operations, cash flows and financial condition.
We derive a significant portion of our revenue from operations from customers outside India, particularly from North America and Europe. While revenue from operations from North America represented 54.80%, 60.08% and 55.19% of our revenue from operations in Fiscals 2026, 2025 and 2024, respectively, revenue from operations from Europe represented 29.67%, 22.24% and 27.19% of our revenue from operations in Fiscals 2026, 2025 and 2024, respectively. Any adverse developments in these international markets could impact the demand for our solutions which in turn could have an adverse effect on our business, financial condition, cash flows and results of operations.
We depend on certain key customers for a significant portion of our revenue from operations (our top ten customers contributed to 43.29%, 35.41% and 31.36% of our revenue from operations in Fiscals 2026, 2025 and 2024, respectively). Any decrease in revenue from any of our key customers or any loss of these customers may adversely affect our business, results of operations, cash flows and financial condition.
We are subject to strict technical specifications and quality requirements, and our manufacturing facilities and equipment are subject to periodic inspections and audits by regulatory authorities and our customers. Any manufacturing or quality control failure may subject us to regulatory action or termination of customer contracts any of which could have an adverse effect on our reputation, business, results of operations, cash flows and financial condition.
We are highly dependent on our skilled personnel, in particular our scientific personnel, for our day-to-day operations. The loss of, or our inability to attract or retain such persons may have a material adverse effect on our business, results of operations, cash flows and financial condition.
Any inability of our customers to develop or manufacture commercially viable drugs may adversely affect outsourcing needs and our development and manufacturing revenue and consequently, our business, financial condition, results of operations and cash flows.
Our R&D and manufacturing facilities are essential to our business. Any disruption or interruption in the continuous operations of our R&D and manufacturing facilities would have a material adverse effect on our business, results of operations, cash flows and financial condition.
We compete in a highly competitive market and any failure to successfully compete with other industry players or to maintain pricing discipline in the face of competitive pressures could materially adversely affect our margins, business, results of operations, cash flows and financial condition.
Our failure to protect our customers' trade secrets, sensitive information and other confidential information, or any infringement or misappropriation claims, could erode our competitive advantage and adversely affect our reputation, business, results of operations, cash flows and financial condition.
We rely on domestic and international third-party suppliers for our raw materials that contribute to a significant portion of our total purchases (our top ten suppliers contributed to 32.91%, 33.73% and 27.56% of our total purchases in Fiscals 2026, 2025 and 2024, respectively). Any inability to retain key suppliers or identify alternate sourcing arrangements for critical raw materials could adversely affect our business, results of operations, cash flows and financial condition.
